Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

13.75
+0.38002.84%
Post-market: 14.220.4700+3.42%19:48 EST
Volume:38.86K
Turnover:535.66K
Market Cap:2.40B
PE:5.19
High:14.00
Open:13.52
Low:13.46
Close:13.37
52wk High:19.50
52wk Low:11.51
Shares:174.43M
Float Shares:104.00M
Volume Ratio:0.77
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.65
EPS(LYR):0.2205
ROE:46.90%
ROA:-0.81%
PB:1.95
PE(LYR):62.35

Loading ...

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

GlobeNewswire
·
Dec 05, 2025

AI-Powered Event Notifications Might Change the Case for Investing in Paychex (PAYX)

Simply Wall St.
·
Dec 01, 2025

HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting

Stock News
·
Nov 27, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
Nov 19, 2025

New Dayforce Report Uncovers America’s Growing Retirement Divide

GlobeNewswire
·
Nov 18, 2025

HUTCHMED (00013) Narrows YTD Gain to 5%: When Will the "Bull Market Misser" Rebound?

Stock News
·
Nov 12, 2025

Orient Securities Maintains "Buy" Rating on HUTCHMED (00013), Highlights Innovative ATTC Platform

Stock News
·
Nov 10, 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire
·
Nov 09, 2025

CICC Remains a Buy on HUTCHMED (China) (HCM)

TIPRANKS
·
Nov 08, 2025

CICC Maintains Outperform Rating on HUTCHMED (00013) with Target Price of HK$30

Stock News
·
Nov 07, 2025

HUTCHMED Completes Enrollment for Global Phase 3 Study of Lung Cancer Combination Therapy

MT Newswires Live
·
Nov 05, 2025

HUTCHMED (00013) Completes Patient Enrollment for Global Phase III SAFFRON Study Evaluating ORPATHYS® (Savolitinib) and TAGRISSO® (Osimertinib) Combination Therapy in MET-Overexpressed/Amplified NSCLC Post-TAGRISSO® Progression

Stock News
·
Nov 05, 2025

Cytokinetics to Participate in November Investor Conferences

GlobeNewswire
·
Nov 05, 2025

HUTCHMED (00013.HK) Rises Over 3%

Deep News
·
Nov 04, 2025

Hutchmed highlights pipeline, business progress at R&D Updates event

TIPRANKS
·
Nov 03, 2025

HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates

Stock News
·
Nov 03, 2025

Asure’s Strong Growth and Profitability Drive Buy Rating Amid Challenging HCM Environment

TIPRANKS
·
Nov 01, 2025

Press Release: Terrestrial Energy Inc. Completes Business Combination with HCM II Acquisition Corp.

Dow Jones
·
Oct 29, 2025

HUTCHMED (00013) Unveils HMPL-A251 Data at AACR-NCI-EORTC Conference

Stock News
·
Oct 23, 2025

HCM II Acquisition shareholders approve combination with Terrestrial Energy

TIPRANKS
·
Oct 21, 2025